This HTML5 document contains 41 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n11http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00209805%3A_____%2F13%3A%230000434%21RIV14-MSM-00209805/
dctermshttp://purl.org/dc/terms/
n15http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n12http://linked.opendata.cz/resource/domain/vavai/projekt/
n7http://linked.opendata.cz/resource/domain/vavai/subjekt/
n6http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n8http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n20http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n14http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00209805%3A_____%2F13%3A%230000434%21RIV14-MSM-00209805
rdf:type
skos:Concept n6:Vysledek
rdfs:seeAlso
http://jco.ascopubs.org/content/31/25/3091.full.pdf
dcterms:description
Purpose is to determine whether adjuvant tamoxifen treatment for breast cancer (BC) is associated with reduced contralateral breast cancer (CBC) risk for BRCA1 and/or BRCA2 mutation carriers. Analysis of pooled observational cohort data, self-reported at enrollment and at follow-up from the International BRCA1, and BRCA2 Carrier Cohort Study, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, and Breast Cancer Family Registry. Eligible women were BRCA1 and BRCA2 mutation carriers diagnosed with unilateral BC since 1970 and no other invasive cancer or tamoxifen use before first BC. Hazard ratios (HRs) for CBC associated with tamoxifen use were estimated using Cox regression, adjusting for year and age of diagnosis, country, and bilateral oophorectomy and censoring at contralateral mastectomy, death, or loss to follow-up. Of 1,583 BRCA1 and 881 BRCA2 mutation carriers, 383 (24%) and 454 (52%), respectively, took tamoxifen after first BC diagnosis. There were 520 CBCs over 20,104 person-years of observation. The adjusted HR estimates were 0.38 (95% CI, 0.27 to 0.55) and 0.33 (95% CI, 0.22 to 0.50) for BRCA1 and BRCA2 mutation carriers, respectively. After left truncating at recruitment to the cohort, adjusted HR estimates were 0.58 (95% CI, 0.29 to 1.13) and 0.48 (95% CI, 0.22 to 1.05) based on 657 BRCA1 and 426 BRCA2 mutation carriers with 100 CBCs over 4,392 person-years of prospective follow-up. HRs did not differ by estrogen receptor status of the first BC (missing for 56% of cases). This study provides evidence that tamoxifen use is associated with a reduction in CBC risk for BRCA1 and BRCA2 mutation carriers. Further follow-up of these cohorts will provide increased statistical power for future prospective analyses. Purpose is to determine whether adjuvant tamoxifen treatment for breast cancer (BC) is associated with reduced contralateral breast cancer (CBC) risk for BRCA1 and/or BRCA2 mutation carriers. Analysis of pooled observational cohort data, self-reported at enrollment and at follow-up from the International BRCA1, and BRCA2 Carrier Cohort Study, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, and Breast Cancer Family Registry. Eligible women were BRCA1 and BRCA2 mutation carriers diagnosed with unilateral BC since 1970 and no other invasive cancer or tamoxifen use before first BC. Hazard ratios (HRs) for CBC associated with tamoxifen use were estimated using Cox regression, adjusting for year and age of diagnosis, country, and bilateral oophorectomy and censoring at contralateral mastectomy, death, or loss to follow-up. Of 1,583 BRCA1 and 881 BRCA2 mutation carriers, 383 (24%) and 454 (52%), respectively, took tamoxifen after first BC diagnosis. There were 520 CBCs over 20,104 person-years of observation. The adjusted HR estimates were 0.38 (95% CI, 0.27 to 0.55) and 0.33 (95% CI, 0.22 to 0.50) for BRCA1 and BRCA2 mutation carriers, respectively. After left truncating at recruitment to the cohort, adjusted HR estimates were 0.58 (95% CI, 0.29 to 1.13) and 0.48 (95% CI, 0.22 to 1.05) based on 657 BRCA1 and 426 BRCA2 mutation carriers with 100 CBCs over 4,392 person-years of prospective follow-up. HRs did not differ by estrogen receptor status of the first BC (missing for 56% of cases). This study provides evidence that tamoxifen use is associated with a reduction in CBC risk for BRCA1 and BRCA2 mutation carriers. Further follow-up of these cohorts will provide increased statistical power for future prospective analyses.
dcterms:title
Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers
skos:prefLabel
Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers
skos:notation
RIV/00209805:_____/13:#0000434!RIV14-MSM-00209805
n6:predkladatel
n7:ico%3A00209805
n4:aktivita
n18:P
n4:aktivity
P(ED2.1.00/03.0101)
n4:cisloPeriodika
25
n4:dodaniDat
n14:2014
n4:domaciTvurceVysledku
n15:1030779
n4:druhVysledku
n16:J
n4:duvernostUdaju
n13:S
n4:entitaPredkladatele
n11:predkladatel
n4:idSjednocenehoVysledku
109811
n4:idVysledku
RIV/00209805:_____/13:#0000434
n4:jazykVysledku
n19:eng
n4:klicovaSlova
estrogen receptor beta; ovarian cancer; endometrial cancer; genetics
n4:klicoveSlovo
n5:estrogen%20receptor%20beta n5:ovarian%20cancer n5:genetics n5:endometrial%20cancer
n4:kodStatuVydavatele
US - Spojené státy americké
n4:kontrolniKodProRIV
[39B5FEAF91E3]
n4:nazevZdroje
Journal of Clinical Oncology
n4:obor
n20:FD
n4:pocetDomacichTvurcuVysledku
1
n4:pocetTvurcuVysledku
36
n4:projekt
n12:ED2.1.00%2F03.0101
n4:rokUplatneniVysledku
n14:2013
n4:svazekPeriodika
31
n4:tvurceVysledku
Foretová, Lenka
n4:wos
000330540600010
s:issn
0732-183X
s:numberOfPages
9
n8:doi
10.1200/JCO.2012.47.8313